These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22332909)

  • 1. Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?
    Jöhrer K; Hofbauer SW; Zelle-Rieser C; Greil R; Hartmann TN
    Expert Opin Biol Ther; 2012 Apr; 12(4):425-41. PubMed ID: 22332909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch-ing from T-cell to B-cell lymphoid malignancies.
    Mirandola L; Comi P; Cobos E; Kast WM; Chiriva-Internati M; Chiaramonte R
    Cancer Lett; 2011 Sep; 308(1):1-13. PubMed ID: 21652011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation.
    Ghia P; Chiorazzi N; Stamatopoulos K
    J Intern Med; 2008 Dec; 264(6):549-62. PubMed ID: 19017179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation.
    Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G
    Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination.
    López-Giral S; Quintana NE; Cabrerizo M; Alfonso-Pérez M; Sala-Valdés M; De Soria VG; Fernández-Rañada JM; Fernández-Ruiz E; Muñoz C
    J Leukoc Biol; 2004 Aug; 76(2):462-71. PubMed ID: 15155773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact.
    Schröttner P; Leick M; Burger M
    Ann Hematol; 2010 May; 89(5):437-46. PubMed ID: 20020127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia.
    Bojarska-Junak A; Rolinski J; Wasik-Szczepaneko E; Kaluzny Z; Dmoszynska A
    Haematologica; 2002 May; 87(5):490-9. PubMed ID: 12010662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional expression of the calcitonin receptor by human T and B cells.
    Cafforio P; De Matteo M; Brunetti AE; Dammacco F; Silvestris F
    Hum Immunol; 2009 Sep; 70(9):678-85. PubMed ID: 19445988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma.
    Abdi J; Engels F; Garssen J; Redegeld F
    Crit Rev Oncol Hematol; 2011 Nov; 80(2):225-40. PubMed ID: 21236697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunologic phenotype of lymphocytes in chronic B-cell lymphocytic leukemia. I. B- and T-lymphocytes in chronic lymphocytic leukemia].
    Rupniewska ZM; Wach M; Kowal M; Roliński J; Antosz H
    Acta Haematol Pol; 1992; 23(1):21-7. PubMed ID: 1615748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide in lymphomas and chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Pharmacother; 2013 Mar; 14(4):475-88. PubMed ID: 23356486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered constitutive and activation-induced expression of CD95 by B- and T-cells in B-cell chronic lymphocytic leukemia.
    De Fanis U; Dalla Mora L; Romano C; Sellitto A; Tirelli A; Lucivero G
    Haematologica; 2002 Mar; 87(3):325-7. PubMed ID: 11869948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
    Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
    Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide for the treatment of B-cell malignancies.
    Chanan-Khan AA; Cheson BD
    J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.
    Di Ianni M; Moretti L; Terenzi A; Bazzucchi F; Del Papa B; Bazzucchi M; Ciurnelli R; Lucchesi A; Sportoletti P; Rosati E; Marconi PF; Falzetti F; Tabilio A
    Cytotherapy; 2009; 11(1):86-96. PubMed ID: 19153855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.
    Alfonso-Pérez M; López-Giral S; Quintana NE; Loscertales J; Martín-Jiménez P; Muñoz C
    J Leukoc Biol; 2006 Jun; 79(6):1157-65. PubMed ID: 16603585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival.
    Giuliani N; Bonomini S; Romagnani P; Lazzaretti M; Morandi F; Colla S; Tagliaferri S; Lasagni L; Annunziato F; Crugnola M; Rizzoli V
    Haematologica; 2006 Nov; 91(11):1489-97. PubMed ID: 17082008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Genome Sciences announces clearance of IND application for LymphoRad.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):246-7. PubMed ID: 12113047
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
    Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
    Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.